Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
An announcement from Inventiva ( (IVA) ) is now available.
On June 1 and 2, 2026, Inventiva launched a comprehensive refinancing, combining a $4.40-per-ADS equity offering of 27,272,727 American Depositary Shares and a new debt facility of up to €130 million, plus an uncommitted €20 million tranche, with an initial €75 million drawdown. Net proceeds from the offering are expected to reach about $110.8 million (€95.2 million), with closing targeted for June 5, 2026, underpinning the company’s funding needs for its late-stage MASH program.
In parallel, Inventiva agreed with the European Investment Bank to fully repay approximately €63 million outstanding under its prior loan and buy back a large portion of EIB warrants for €50 million, while issuing new, simplified warrants subject to shareholder approval expected by October 31, 2026. The transaction is designed to sharply reduce potential share dilution and remove restrictive anti-dilution and put-option features, improving financing flexibility, though failure to complete it by June 30, 2026 would restore the EIB’s original rights.
Ahead of announcing this financing on June 2, 2026, Inventiva temporarily halted trading of its ordinary shares on Euronext Paris at its own request, with trading expected to resume the same day around 3:30 p.m. CEST when ADS trading opened on Nasdaq. The coordinated halt and resumption aimed to ensure an orderly market as the refinancing terms became public, balancing transparency for investors with the need to stabilize trading during a pivotal capital raise.
The most recent analyst rating on (IVA) stock is a Buy
with a $11.00 price target.
To see the full list of analyst forecasts on Inventiva stock,
see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
The score is constrained primarily by weak financial performance (large ongoing losses, consistent cash burn, negative equity and rising debt). Technicals also detract due to a clear downtrend (price below key moving averages and negative MACD), partially tempered by oversold readings. The earnings call provides a meaningful offset via operational progress and defined clinical/readout timing plus stated cash runway, but it comes with material clinical and financing dependencies.
To see Spark’s full report on IVA stock,
click here.
More about Inventiva
Inventiva is a clinical-stage biopharmaceutical company developing orally administered small molecules for metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, lanifibranor, a novel pan-PPAR agonist, is in the pivotal Phase 3 NATiV3 trial for adult MASH patients. Inventiva’s shares trade on Euronext Paris and the Nasdaq Global Market under the ticker IVA.
The company’s focus on MASH, a progressive chronic liver disease with significant unmet medical need, positions it within a highly competitive but fast-growing segment of metabolic and liver therapies. Dual listings in Europe and the U.S. broaden its investor base and facilitate access to international capital markets, an important factor given its capital-intensive late-stage development pipeline.
Average Trading Volume: 352,918
Technical Sentiment Signal: Hold
Current Market Cap: $832.4M
See more data about IVA stock on TipRanks’ Stock Analysis page.